S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:PYPDRepare Therapeutics Stock Price, Forecast & News

$13.95
+0.05 (+0.36 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.72
Now: $13.95
$14.42
50-Day Range N/A
52-Week Range
$13.35
Now: $13.95
$19.45
Volume56,222 shs
Average Volume71,830 shs
Market Capitalization$237.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting à tri-calcium phosphate granule for bone related infections applications; and BONYPIDÂ-500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PYPD
CUSIPN/A
CIKN/A
Phone972-74-719-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees57
Market Cap$237.79 million
Next Earnings DateN/A
OptionableNot Optionable
$13.95
+0.05 (+0.36 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PYPD News and Ratings via Email

Sign-up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Repare Therapeutics (NASDAQ:PYPD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Repare Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Repare Therapeutics
.

What price target have analysts set for PYPD?

3 brokers have issued 1 year price objectives for Repare Therapeutics' shares. Their forecasts range from $22.00 to $30.00. On average, they expect Repare Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 79.2% from the stock's current price.
View analysts' price targets for Repare Therapeutics
.

Has Repare Therapeutics been receiving favorable news coverage?

News articles about PYPD stock have trended neutral on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Repare Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Repare Therapeutics
.

Who are some of Repare Therapeutics' key competitors?

Who are Repare Therapeutics' key executives?

Repare Therapeutics' management team includes the following people:
  • Mr. Amir Weisberg, CEO & Director (Age 64)
  • Ms. Dikla Czaczkes Akselbrad, Exec. VP & CFO (Age 47)
  • Dr. Noam Emanuel, Chief Scientific Officer (Age 61)
  • Dr. Shaul Mukhtar Ph.D., Exec. VP & COO (Age 64)
  • Dr. Taunia Markvicka, Chief Operating Officer - PolyPid Inc. (Age 51)

When did Repare Therapeutics IPO?

(PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

What is Repare Therapeutics' stock symbol?

Repare Therapeutics trades on the NASDAQ under the ticker symbol "PYPD."

When did Repare Therapeutics' quiet period expire?

Repare Therapeutics' quiet period expired on Wednesday, August 5th. Repare Therapeutics had issued 3,750,000 shares in its initial public offering on June 26th. The total size of the offering was $60,000,000 based on an initial share price of $16.00. During Repare Therapeutics' quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Repare Therapeutics?

Shares of PYPD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Repare Therapeutics' stock price today?

One share of PYPD stock can currently be purchased for approximately $13.95.

How big of a company is Repare Therapeutics?

Repare Therapeutics has a market capitalization of $237.79 million. Repare Therapeutics employs 57 workers across the globe.

What is Repare Therapeutics' official website?

The official website for Repare Therapeutics is www.polypid.com.

How can I contact Repare Therapeutics?

Repare Therapeutics' mailing address is 20 HAMAGSHIMIM STREET MATALON CENTER, PETACH TIKVA L3, 49348. The company can be reached via phone at 972-74-719-5700.

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.